UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):June 16, 2016
FORTRESS BIOTECH, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-35366 | 20-5157386 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 2 Gansevoort Street, 9th Floor, New York, New York | 10014 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:(781) 652-4500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
Fortress Biotech, Inc. (the “Company”) held its 2016 annual meeting of stockholders on June 16, 2016. At the meeting, stockholders elected the following seven members to the Company’s Board of Directors to serve until the Company’s next annual meeting of stockholders or until their successors have been elected and qualified, based on the following votes:
| Nominee | | For | | Against | | Abstain | | Broker
Non-Votes |
| Lindsay A. Rosenwald, M.D. | | 22,633,932 | | 2,410,294 | | 13,245 | | 18,100,681 |
| Eric K. Rowinsky, M.D. | | 23,632,126 | | 1,411,274 | | 14,071 | | 18,100,681 |
| Jimmie Harvey, Jr., M.D. | | 22,634,148 | | 1,401,052 | | 1,022,271 | | 18,100,681 |
| Malcolm Hoenlein | | 22,622,787 | | 1,412,408 | | 1,022,276 | | 18,100,681 |
| Dov Klein | | 22,427,413 | | 1,607,782 | | 1,022,276 | | 18,100,681 |
| J. Jay Lobell | | 22,425,933 | | 1,608,262 | | 1,023,276 | | 18,100,681 |
| Michael S. Weiss | | 22,543,662 | | 2,499,738 | | 14,071 | | 18,100,681 |
At the meeting, stockholders also ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. The vote for such ratification was 42,819,465 shares for, 284,356 shares against, 54,331 shares abstaining, and no broker non-votes.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | FORTRESS BIOTECH, INC. | |
| | | |
| | | |
| Date: June 21, 2016 | /s/ Lindsay A. Rosenwald | |
| | Lindsay A. Rosenwald, M.D., | |
| | Chairman, President and Chief Executive Officer | |
